Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Breast Cancer, Lung Cancer, Skin Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Pancreatic Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 16 - 100 |
| Updated: | 12/20/2018 |
| Start Date: | January 30, 2018 |
| End Date: | December 31, 2030 |
Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential Future Therapy
Background:
Researchers want to test if certain cells can be re-programmed into stem cells. Stem cells
can keep reproducing for a long time. Cells made by stem cells can be turned into different
types of cells. These include cancer-fighting cells, skin cells, etc. The stem cells
generated in this study will be used to make specific tumor-fighting cells that can recognize
different types of mutations in cancer cells. They may also help identify new tumor mutations
that may not have been identified yet.
Objectives:
To test if a certain type of tumor-fighting cells can be re-programmed into stem cells.
Eligibility:
Participants in another Surgery Branch protocol who are at least 16 years old
Design:
Participants already gave samples of blood and/or tumor tissue in the other protocol. They do
not need to come back to the clinic or give any other samples.
Participants will give consent for their samples to be used in this study.
Researchers will obtain cells from the samples. They will grow those cells in the lab. They
will create stem cells from them.
Researchers will do genetic tests on the samples.
Most tests will not show important health results. But if they do, the participant will be
invited to talk to a genetic counselor and get more detailed testing to confirm the results.
Some of the samples and results will be stored indefinitely. They may be used in future
research. No personal information will be stored with them.
Researchers want to test if certain cells can be re-programmed into stem cells. Stem cells
can keep reproducing for a long time. Cells made by stem cells can be turned into different
types of cells. These include cancer-fighting cells, skin cells, etc. The stem cells
generated in this study will be used to make specific tumor-fighting cells that can recognize
different types of mutations in cancer cells. They may also help identify new tumor mutations
that may not have been identified yet.
Objectives:
To test if a certain type of tumor-fighting cells can be re-programmed into stem cells.
Eligibility:
Participants in another Surgery Branch protocol who are at least 16 years old
Design:
Participants already gave samples of blood and/or tumor tissue in the other protocol. They do
not need to come back to the clinic or give any other samples.
Participants will give consent for their samples to be used in this study.
Researchers will obtain cells from the samples. They will grow those cells in the lab. They
will create stem cells from them.
Researchers will do genetic tests on the samples.
Most tests will not show important health results. But if they do, the participant will be
invited to talk to a genetic counselor and get more detailed testing to confirm the results.
Some of the samples and results will be stored indefinitely. They may be used in future
research. No personal information will be stored with them.
Background:
-T cells are potentially curative for patients with metastatic cancer, but many patients with
cancer have T cells that are terminally differentiated , a condition associated with
treatment failure. We have observed that less differentiated T cells have a greater
capacity to proliferate, persist and destroy large cancer deposits. Advances in
regenerative medicine might allow the generation of rejuvenated T cells from induced
pluripotent stem cells (iPSC).
Objective:
-To reprogram patient specimens into induced pluripotent stem cells (iPSC) and
differentiate them into different types of somatic cells with the goal to produce cancer
antigen-specific T cells.
-To make stored specimens and/or data available to approved research laboratories and
investigators.
Eligibility:
- Patients enrolled in protocol 03-C-0277
- Patients willing to be consented on this protocol
Design:
- Cell and tissue obtained previously under protocol 03-C-2077
- Reprogramming of cell and tissue into iPSC lines
- Derivation of iPSC lines into T cells and iPSC progeny capable of supporting T cell
differentiation
- Generation of an iPSC-derived thymic organoid
- Screening of tumor antigen specificity for regenerated T cells
- In vivo analysis of regenerated T cells
-T cells are potentially curative for patients with metastatic cancer, but many patients with
cancer have T cells that are terminally differentiated , a condition associated with
treatment failure. We have observed that less differentiated T cells have a greater
capacity to proliferate, persist and destroy large cancer deposits. Advances in
regenerative medicine might allow the generation of rejuvenated T cells from induced
pluripotent stem cells (iPSC).
Objective:
-To reprogram patient specimens into induced pluripotent stem cells (iPSC) and
differentiate them into different types of somatic cells with the goal to produce cancer
antigen-specific T cells.
-To make stored specimens and/or data available to approved research laboratories and
investigators.
Eligibility:
- Patients enrolled in protocol 03-C-0277
- Patients willing to be consented on this protocol
Design:
- Cell and tissue obtained previously under protocol 03-C-2077
- Reprogramming of cell and tissue into iPSC lines
- Derivation of iPSC lines into T cells and iPSC progeny capable of supporting T cell
differentiation
- Generation of an iPSC-derived thymic organoid
- Screening of tumor antigen specificity for regenerated T cells
- In vivo analysis of regenerated T cells
- INCLUSION CRITERIA:
- Patients with a cancer diagnosis enrolled on protocol 03-C-0277.
- Willing and able to provide informed consent
- Patients must be greater than or equal to 16 years of age.
EXCLUSION CRITERIA:
-Healthy donors enrolled on protocol 03-C-0277.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
301-496-2563
Phone: 866-820-4505
National Institutes of Health Clinical Center The National Institutes of Health (NIH) Clinical Center in...
Click here to add this to my saved trials
